The relationship between serum levels of epidermal growth factor and ß-human chorionic gonadotropin and the type and prognosis of ectopic pregnancy.

PURPOSE: This work aimed to explore the relationship between epidermal growth factor (EGF) and ß-human chorionic gonadotropin (ß-HCG) and ectopic pregnancy types and impact on prognosis. METHODS: Twenty women with normal pregnancies (NPs) were recruited as control group, and twenty women each with tubal pregnancy (TP) and cervical pregnancy (CP) were recruited. Blood samples were collected to detect EGF and ß-HCG. Data on length of hospital stay and incidence of complications were collected. The differences in serum EGF and ß-HCG levels were compared among groups and within various types of ectopic pregnancy using analysis of variance and Pearson correlation analysis. RESULTS: Serum EGF and ß-HCG were notably lower in TP and CP group vs. controls (P < 0.05). In subgroup analysis within the types of ectopic pregnancy, serum EGF levels were drastically higher in TP group vs. CP group (P < 0.05). Serum EGF levels were negatively correlated with pregnancy outcomes and incidence of complications (P < 0.05). In patients with TP and CP, serum EGF and ß-HCG recovery time and hospital stay differed drastically (P < 0.05). Serum EGF and ß-HCG levels showed optimal cutoff values identified at 2.65 µg/L and 11,745.35 IU/L, respectively. The corresponding area under the curve (AUC) values were 0.885 and 0.841. CONCLUSION: Elevated levels of EGF may be associated with the occurrence of ectopic pregnancy and may impact the type of ectopic pregnancy, pregnancy outcomes, and the incidence of complications. Further clinical research is warranted to investigate these findings.

The Clinical Effects of Metronidazole Vaginal Effervescent Tablets Combined with Kushen Suppository in the Treatment of Trichomonas Vaginitis.

Objective: The aim of this study was to explore the clinical effects of metronidazole vaginal effervescent tablets combined with Kushen suppository in the treatment of Trichomonas vaginitis. Methods: Ninety patients with trichomoniasis admitted to our hospital from January 2019 to January 2020 were prospectively analyzed and randomly divided into a control group (n = 45) treated with metronidazole vaginal effervescent tablets and an experimental group (n = 45) treated with Kushen suppository on top of the control group using the random number table method. The clinical effects, inflammatory factors, and microcirculation indexes were compared. We assessed patient's vaginal health by Vaginal Health Score Scale (VHS) before and after treatment and estimated their quality of life according to Generic Quality of Life Inventory-74 (GQOLI-74). A follow-up visit was conducted to compare patient's recurrence 3 months after treatment. Results: Distinctly higher total clinical effective of the experimental group compared with that of the control group was obtained (P < 0.05); the serum level of inflammatory factors of the experimental group was dramatically lower than that of the control group after treatment (P < 0.001); the experimental group experienced a favorable microcirculation index in comparison with the control group (P < 0.001); superior VHS (P < 0.001) and GQOLI-74 (P < 0.05) scores of the experimental group after treatment compared to those of the control group were observed; the recurrence rate of the experimental group 3 months after treatment was significantly decreased in comparison with that of the control group (P < 0.05). Conclusion: Metronidazole vaginal effervescent tablets combined with Kushen suppository can effectively improve the clinical symptoms of patients with trichomonas vaginitis, abate patient's inflammatory reaction, and raise their quality of life, which is worthy of promotion.

[The relativity of vascular endothelium growth factor receptor-1 and preeclampsia].

OBJECTIVES: (1) To investigate the levels of the serum soluble endothelial growth factor receptor-1 in women with preeclampsia and compare the difference between the groups of the mild preeclampsia, severe preeclampsia and eclampsia. For more, to analyze the relativity between the levels of the serum soluble vascular growth factor receptor-1 and preeclampsia. (2) To detect the expression of the membrane-bound VEGFR-1 protein in the placenta tissue of the women with preeclampsia and compare the difference between the groups of the mild preeclampsia, severe preeclampsia and eclampsia, Then to analyze the relativity between the expression of the membrane-bound endothelial growth factor receptor-1 and preeclampsia. METHODS: (1) The serum levels of sVEGFR-1 in 10 women with mild preeclampsia, 10 women with severe preeclampsia, 10 women with eclampsia, 10 women without preeclampsia were detected by the quantitative sandwich enzyme immunoassay technique. (2) Immunohistochemistry and quantitative analysis were used to detect membrane-bound VEGFR-1 contents and distribution in the placenta tissue. RESULTS: (1) The results showed that the serum sVEGFR-1 levels of all preeclampsia groups were relatively higher than those of control group (P < 0.05) and that there were significant differences between the groups of the mild preeclampsia, severe preeclampsia and eclampsia. (2) In placentas, the positive staining was detected predominantly in the membranes of villus syncytiotrophoblast cells, extravillous trophoblast cells, and villus endothelial cells. In fetal membranes, the positive staining was detected predominantly in amnionic endothelial cells. (3) The contents of membrane-bound VEGFR-1 in placenta of preeclampsia groups were relatively lower than that of control group. There were significant differences between membrane-bound VEGFR-1 contents of the mild preeclampsia,severe preeclampsia and eclampsia (P < 0.05). (4) The ratio of the sVEGFR-1 concentration in serum and the membrane-bound VEGFR-1 contents in placenta of preeclampsia groups (sVEGFR-1/ membrane-bound VEGFR-1) was relatively higher than that of control group (P < 0.05) and there were significant differences between the groups of the mild preeclampsia, severe preeclampsia and eclampsia (P < 0.05). CONCLUSIONS: (1) The serum sVEGFR-1 levels of preeclampsia groups were relatively higher than those of control group, the VEGFR-1 may be related to preeclampsia. (2) The contents of membrane-bound VEGFR-1 in placenta of preeclampsia groups were relatively lower than that of control group, the membrane-bound VEGFR-1 may relate to preeclampsia. (3) The ratio of the sVEGFR-1 concentration in serum and the membrane-bound VEGFR-1 contents in placenta of preeclampsia groups (sVEGFR-1/membrane-bound VEGFR-1) was relatively higher than that of control group, the preeclampsia may contribute to VEGFR-1/ PLGF and sVEGFR-1/membrane-bound.